Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Alain Saraux; Thomas Barnetche; Guy Baudens; Isabelle Idier; Flore Delaporte; Pascal Hilliquin

Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Alain Saraux ^{1, 2} Thomas Barnetche ³ Guy Baudens ⁴ Isabelle Idier ⁵ Flore Delaporte ⁶ Pascal Hilliquin ⁷

1 CHU - BREST - Rhumato - CHRU Brest - Service de Rhumatologie

2 LBAI - Lymphocyte B et Auto-immunité

3 SERVICE DE RHUMATOLOGIE - Rhumatologie Bordeaux

4 Cabinet de Rhumatologie, Valenciennes

5 Chugai Pharma France, Paris La Défense

6 Laboratoire Roche [Boulogne-Billancourt]

7 Centre Hospitalier Sud Francilien

Document type :

Poster communications

Domain :

Life Sciences [q-bio] / Immunology

Complete list of metadatas

https://hal.univ-brest.fr/hal-02151122
Contributor : Geneviève Michel <>
Submitted on : Friday, June 7, 2019 - 4:59:02 PM
Last modification on : Saturday, June 8, 2019 - 1:35:48 AM

Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Identifiers

Collections

Citation

Export

Metrics

12

Contact

Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Identifiers

Collections

Citation

Export

Share

Metrics

12

Contact